Filana Therapeutics (FLNA) Total Non-Current Liabilities (2010 - 2026)
Filana Therapeutics (FLNA) posted quarterly Total Non-Current Liabilities of $40.2 million for Q2 2026, down 15.16% year-over-year from $47.3 million in Q2 2025, and little changed quarter-over-quarter from $40.1 million in Q1 2026.
Filana Therapeutics (FLNA) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Filana Therapeutics' Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $40.2 million for Q2 2026.
- In Q2 2026, Total Non-Current Liabilities fell 15.16% year-over-year to $40.2 million; the TTM figure through Jun 2026 stood at $40.2 million (down 15.16% YoY), while the FY2025 annual figure was $43.8 million, up 273.06% from the prior year.
- Total Non-Current Liabilities for Q2 2026 stood at $40.2 million, roughly flat from $40.1 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $57.0 million in Q3 2024, with the low at $6.9 million in Q1 2022.
- The 5-year median for Total Non-Current Liabilities is $14.2 million (2023), against an average of $25.2 million.
- The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities sank 43.99% in 2022, then jumped 273.06% in 2025.
- Filana Therapeutics' Total Non-Current Liabilities stood at $7.1 million in 2022, then jumped by 99.99% to $14.2 million in 2023, then retreated by 17.22% to $11.8 million in 2024, then surged by 273.06% to $43.8 million in 2025, then decreased by 8.39% to $40.2 million in 2026.
- Business Quant data shows FLNA's Total Non-Current Liabilities at $40.2 million in Q2 2026, $40.1 million in Q1 2026, and $43.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 9.32 Bn |
| 10 | Filana Therapeutics | 46.14 Mn | 46.14 Mn | - | 40.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40.16 Mn |
| Mar 31, 2026 | 40.12 Mn |
| Dec 31, 2025 | 43.83 Mn |
| Sep 30, 2025 | 48.05 Mn |
| Jun 30, 2025 | 47.33 Mn |
| Mar 31, 2025 | 13.24 Mn |
| Dec 31, 2024 | 11.75 Mn |
| Sep 30, 2024 | 57.03 Mn |
| Dec 31, 2023 | 14.20 Mn |
| Sep 30, 2023 | 17.41 Mn |
| Mar 31, 2023 | 13.91 Mn |
| Dec 31, 2022 | 7.10 Mn |
| Sep 30, 2022 | 8.37 Mn |
| Jun 30, 2022 | 8.81 Mn |
| Mar 31, 2022 | 6.90 Mn |
| Dec 31, 2021 | 12.67 Mn |
| Sep 30, 2021 | 6.49 Mn |
| Sep 30, 2011 | 56.67 Mn |
| Jun 30, 2011 | 59.13 Mn |
| Dec 31, 2010 | 65.83 Mn |